Process for the continuous production of active ingredient granules

Abstract

A process for the continuous manufacture of active ingredient granules is provided, the process comprising the steps of: (a) preparing a spray composition by dissolving or dispersing the active ingredient and, optionally, one or more excipients in a liquid; (b) providing solid particles in the process space; (c) introducing droplets of the spray composition into an injection zone of the process space where the liquid evaporates; (d) With the help of process gas jets, solid particles are guided repeatedly past the atomized droplets in the process space, so that at least some of the droplets, which may have already lost part of the liquid they contain, come into contact with the solid particles and form larger solid particles by agglomeration; (e) Removing the active ingredient granules from the process space in the form of solid particles; wherein the active ingredient comprises metformin or an acid addition salt of metformin, particularly metformin hydrochloride.

Description

[Technical field]

[0001] The present invention relates to a method for the continuous production of active ingredient granules, the granules themselves and their use.The present invention also relates to a controlled release dosage form.Metformin and its acid addition salts, in particular metformin hydrochloride, are used as active ingredients. [Background technology]

[0002] After production and purification, active pharmaceutical ingredients are usually obtained in a form that requires extensive further processing steps to convert the active ingredient into a dosage form. In particular, the active ingredient is often not obtained in the form of particles that can be easily formulated.

[0003] Required work-up steps include grinding, polishing, sieving, etc. It is also known to spray-dry a solution of the active ingredient to produce a powder of the active ingredient.

[0004] However, the micronized form of the active ingredient has processing disadvantages, so that, as a rule, the powder of the active ingredient needs to be further processed before it can be manufactured into a dosage form such as a tablet. These disadvantages often include a lack of flowability. Another disadvantage is the low stability of fine powders, which tend to aggregate and clump.

[0005] To avoid such drawbacks, it is common to provide granules.

[0006] Granules containing the active ingredient and optionally one or more excipients can be used to manufacture a dosage form (or administration form), for example by pressing them, alone or together with other ingredients, into a tablet. The particles containing the active ingredient can also be filled into capsules or used in the form of a powder for suspension or solution. They can also be coated.

[0007] Many processes are known for the production of granules. These processes are often carried out as batch processes. A pretreated, usually milled and sieved, active ingredient is used.

[0008] The properties of the granules obtained are not always satisfactory, especially with regard to flowability and stability.

[0009] The prior art also contains proposals to produce granules using a spouted bed apparatus. From US Pat. No. 5,399,433 it is known to produce granules of various materials by introducing a liquid into the solid stream of a spouted bed apparatus. However, this application does not address the particularities of pharmaceutical active substances and the conditions suitable for processing such substances.

[0010] US Pat. No. 5,399,633 relates to a controllable gas inlet device for a spouted bed apparatus.

[0011] US Patent No. 5,399, 67 describes a process for the production of enzyme granules and granules of this type. A spouted bed apparatus is used for production. The application does not address tablet production or the compressibility of the granules.

[0012] Patent document 4 relates to a pharmaceutical substance-containing pellet having a breaking strength of 0.001 Newton or more, a manufacturing process thereof, and a pharmaceutical formulation based on such pellets. It is shown that spherical mannitol pellets with a uniform particle size distribution and a smooth surface can be manufactured from a mannitol solution, and that such pellets can be coated with an active ingredient by layering the active ingredient.

[0013] Although metformin is not mentioned in the above documents, the preparation of dosage forms containing metformin or its acid addition salts, particularly metformin hydrochloride, has been the subject of numerous patent applications and publications.

[0014] Non-Patent Document 1 points out that metformin has poor tabletability and poor flowability, so it is typically wet granulated with a binder before tableting. However, this is considered disadvantageous due to the associated costs. Therefore, a dry process by roller compaction has been proposed.

[0015] Patent document 5 describes a tablet containing metformin hydrochloride, which is made from a dry mixture of metformin hydrochloride and methylcellulose.

[0016] US Pat. No. 5,399,633 describes a mixture of crystalline metformin hydrochloride powder and powdered excipients that can be directly pressed into tablets.

[0017] Non-Patent Document 2 describes the moisture-activated dry granulation of metformin hydrochloride.

[0018] (2003) points out that metformin hydrochloride is hygroscopic and has stability problems, and describes the development of a directly compressible metformin hydrochloride by spray drying, which typically results in a product containing roughly spherical particles less than 50 μm in diameter.

[0019] Furthermore, studies are being conducted on the release of metformin from dosage forms to determine where in the digestive tract the active ingredient should be released to obtain good efficacy, and it has been suggested that release only in the deep intestine would be particularly advantageous (Non-Patent Document 4: https: / / www.diabsite.de / aktuelles / nachrichten / 2016 / 160503b.html).

[0020] Despite all these proposals, there remains a need for improved methods for the manufacture of dosage forms containing metformin. [Prior art documents] [Patent documents]

[0021] [Patent Document 1] DE 10322062 A1 [Patent Document 2] German Patent No. 10004939 [Patent Document 3] International Publication No. 2004 / 108911 [Patent Document 4] International Publication No. 2008 / 110374 [Patent Document 5] U.S. Patent No. 6,667,054 [Patent Document 6] U.S. Patent No. 6,117,451 [Non-patent literature]

[0022] [Non-Patent Document 1] OR Arndt and P. Kleinebudde, AAPS PharmSciTech. 2018 Jul; 19 (5): 2068-2076 [Non-Patent Document 2] H. Takasaki et al., Results in Pharma Sciences 5 (2015) 1-7 [Non-Patent Document 3] BS Barot et al., Acta Pharm. 60 (2010) 165-175 [Non-Patent Document 4] H. Schatz, New Findings on Metformin (2016) Summary of the Invention [Problem to be solved by the invention]

[0023] One object of the present invention is to provide a continuous method for producing granules of an active substance, the active substance being a poorly flowable active substance. The method should allow high throughput and high yield with adjustable granule properties (particle size, moisture, bulk density, etc.).

[0024] Another object is to provide a method which makes it possible to adjust the particle size of the granulate particles.

[0025] A further object of the present invention is to produce granular particles containing at least one active ingredient and exhibiting good flowability.

[0026] It is a further object to provide granules which have a high level of stability, in particular it is desirable for the granule particles not to aggregate or clump together.

[0027] Another object is to provide a method for producing a semi-finished product, which consists of an active ingredient and at least one excipient, and which can preferably be further processed into tablets.

[0028] Another object is to provide a method for producing tablets.

[0029] Finally, it is an object of the present invention to provide a controlled release dosage form and a method for producing the same, in particular a dosage form that releases an active ingredient only in the deep intestine, such as the ileum or colon. [Means for solving the problem]

[0030] According to the invention, it has been found that the continuous production of granules comprising an active ingredient is possible by introducing droplets of a solution or suspension comprising the active ingredient into a process space in which the liquid evaporates, the droplets being guided, with the aid of a suitably temperature-controlled process gas, so that particles already in the process space come into contact with the droplets which still contain at least sufficient liquid to adhere to the particles.

[0031] Thus, the process according to the invention for the continuous production of active ingredient granules comprises the following steps: (a) preparing a spray composition by dissolving or dispersing the active ingredient and, optionally, one or more excipients in a liquid; (b) providing solid particles to the process space; (c) introducing droplets of the spray composition into an injection zone of the process space where the liquid is evaporated; (d) by directing, with the aid of process gas jets, the solid particles repeatedly through the atomized droplets in the process space, at least a part of the droplets, which may have already lost part of their contained liquid, comes into contact with the solid particles and larger solid particles are formed by agglomeration; (e) Removing the active ingredient granules from the process space in the form of solid particles; wherein the active ingredient comprises metformin or an acid addition salt of metformin, in particular metformin hydrochloride.

[0032] In contrast to the production of particles by spray drying in a conventional spray tower, according to the present invention the formed particles are circulated in a process space by repeated coalescence of the solution or dispersion droplets and evaporation of the liquid until the desired size is reached.

[0033] Thus, the method according to the invention allows for controlled particle growth.

[0034] The resulting granules can be processed into tablets and have improved properties compared to known granules, especially with regard to stability and flowability.

[0035] The granules can also be processed into coated dosage forms, particularly dosage forms that release the active ingredient only in the ileum or colon.

[0036] The present invention will now be described in more detail with reference to the drawings. [Brief description of the drawings]

[0037] [Figure 1] 1 shows a schematic representation of a system for carrying out the method according to the invention; [Diagram 2] A typical particle size distribution is shown. [Diagram 3] A micrograph of a typical sample is shown. [Figure 4] 4 shows a micrograph of another sample. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0038] The granule particles produced according to the present invention contain an active ingredient (or active ingredient). The active ingredient comprises metformin or one of its acid addition salts, in particular metformin hydrochloride. According to one embodiment, the active ingredient is metformin or one of its acid addition salts, in particular metformin hydrochloride.

[0039] According to one embodiment, the granule particles consist of an active ingredient.

[0040] In addition to the active ingredient, the granule particles can also contain one or more excipients.As the excipient, any pharma- ceutically suitable excipient can be used.In particular, the excipients that are usually used in the manufacture of granules and tablets are used.Exemplary excipients are binding agents (or binders), lubricants, disintegrants and bulking agents (or fillers).

[0041] A preferred excipient is a binder, which helps hold granule particles together during tablet compression.

[0042] Also, in one embodiment, they support the formation of granular particles, especially when the active ingredient is fully or partially dispersed in a liquid.

[0043] Exemplary binders are polyvinylpyrrolidone (PVP), vinylpyrrolidone-vinyl acetate copolymer, hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC). PVP is preferred.

[0044] The binders can be used, for example, in an amount of 0.1 to 10% by weight, preferably 1 to 7% by weight, in particular 2.5 to 5% by weight, based on the dry matter content.

[0045] In the method according to the invention, a spray composition is sprayed into the process space. The spray composition is a solution or a suspension.

[0046] As the liquid for preparing the solution or suspension, any liquid can be used which does not react or does not react to a significant extent with the active substance and which can be removed under conditions which do not cause or do not cause to a significant extent degradation of the active substance.

[0047] A preferred liquid includes water, in particular the liquid is water.

[0048] The spray composition comprises an active ingredient and optionally one or more excipients. The spray composition preferably comprises a high concentration of the active ingredient and / or excipients.

[0049] The spray composition may also contain components in undissolved form. In a preferred embodiment, the saturation solubility of one or more components is exceeded so that a suspension exists.

[0050] A high dry matter content in the spray composition allows for a high throughput since less liquid must be evaporated to obtain the desired solid particles. A high dry matter content is therefore preferred. It is also preferred to use a suspension.

[0051] The dry matter content of the spray composition is usually at least 25% by weight, preferably at least 40% by weight, in particular at least 50% by weight and most preferably at least 65% by weight.

[0052] Dry matter content refers to the total weight of solids used relative to the total weight of the spray composition.

[0053] The proportion of active ingredient in the dry matter content is typically at least 70% by weight, preferably at least 80% by weight, in particular at least 90% by weight, and may even be 100% by weight.

[0054] In the method of the present invention, droplets are formed from the spray composition. Droplets from a solution or suspension are flowable.

[0055] In the process space they lose liquid by evaporation. Small solid particles can form from the droplets.

[0056] However, a feature of the method according to the invention is that the particles already in the process space are contacted with droplets which still contain at least sufficient liquid, so that they adhere to the particles. When the droplets come into contact with the solid particles, they must at least stick to the surface.

[0057] Such deposition allows for the formation of particles of sufficient size.

[0058] For this purpose, it is essential to allow the previously introduced particles, i.e. particles already introduced in solid form into the process space or particles formed by atomization from the spray composition, to be repeatedly contacted with droplets of the spray composition, so that agglomerates are formed. The solid particles produced according to the invention are typically agglomerates of globules tightly bound to one another.

[0059] In the method according to the invention, the particles are moved in the process space with the aid of process gas jets directed in a defined manner, resulting in a circulating flow of solids, which leads to a region of the device (injection zone) where liquid droplets capable of adhering to the solid particles are introduced.

[0060] According to one embodiment, the particles that have reached the desired size can exit the process space. Smaller particles can remain in the process space and contact the droplets again. According to another embodiment, a portion of the solid particles is removed from the process space. The removed material can be classified and the small particles can be returned to the process space. Excessively large particles can also be returned to the process space after being crushed.

[0061] The process gas can be, for example, air or an inert gas such as nitrogen, carbon dioxide, or a noble gas.

[0062] The process gas jet is essential for both the transport of material and the transport of heat. According to the invention, the temperature of the process gas jet is selected so that the atomized droplets come into contact with already solidified particles and larger particles are formed. In particular, temperature conditions are provided in the process space such that the product is not exposed to temperature conditions that would impair its stability, while at the same time ensuring sufficient drying by evaporation of the liquid.

[0063] The process gas jets typically have a temperature in the range of 60-100° C. The product temperature is typically 30-60° C.

[0064] The process gas jet preferably has a temperature in the range of 70-90° C. The product temperature is preferably 35-50° C.

[0065] In a particularly preferred embodiment, the process gas temperature is 80°C and the product temperature is 40°C.

[0066] According to the invention, the droplets from the spray composition and the solid particles come into contact with each other in a spouted bed. A spouted bed is understood to mean that the fully fluidized solid particles are in a closed solid stream that is stable over time. The spouted bed is generated with the help of process gas jets directed in a defined manner. There are three fluidization states or zones in the spouted bed. In the first zone or ejection zone, the solid particles are accelerated under the action of the process gas jets directed in a defined manner, the particles in this zone move in the direction of the flow of the process gas jets. The process gas jets are usually directed vertically upwards. Thus, in the ejection zone of the spouted bed there is mainly a vertical upward flow. In the subsequent second zone or fountain zone, the particles change the direction of their flow. There is mainly a cross flow. Finally, the particles enter the third zone or return zone. There they move downwards and are again carried along the jets in the first zone, until they are finally back under the influence of the process gas jets directed in a defined manner. In the return zone, the particles typically move under the influence of gravity.

[0067] The spray composition can be sprayed through two-fluid and multi-fluid nozzles. It can also be sprayed through pressure nozzles. Alternatively, dropletization can be achieved using rotary atomizers, jet cutters, ultrasonic dropletizers, and other devices known to those skilled in the art.

[0068] According to the present invention, droplets of the spray composition are sprayed into the process space, and the droplets are dried to form nuclei from solid particles, which are then contacted with further droplets to form particles of a desired size. Alternatively or additionally, solid particles may be supplied from outside into the process. For example, excessively small particles removed from the process may be returned to the process space as seed material. Similarly, excessively large particles or particle agglomerates removed from the process may be crushed by an optional crushing unit and returned to the process space as seed material.

[0069] The particles formed by the method according to the invention are removed from the process space. The material discharge of the finished product from the process space or the material transport to a further downstream process space can take place, for example, in the area of ​​the transition from the cross flow of solids to the downward flow. According to one embodiment, the particles discharged from the process space are not classified. According to another embodiment, the particles discharged from the process space are classified and removed by one or more classifiers.

[0070] The method according to the invention can be carried out, for example, with the aid of an apparatus as described in DE 103 22 062 A1, the contents of which are hereby incorporated by reference.

[0071] The method according to the invention is preferably carried out using an apparatus as shown in the accompanying drawing, which is described in detail below.

[0072] The process gas 10 (usually heated air) is fed into a feed air chamber 17 having a rectangular cross section 9 and a side wall 5 defining the boundary. The process gas 10 is distributed in the feed air chamber 17 and enters the process space 8 in the form of a gas jet 2 through a gap opening 1. The flow of process gas, which preferably enters the gap 1 horizontally, is deflected by a deflector 3, preferably upwards into the process space 8, and enters the device as a kind of free jet. Furthermore, optionally, the cross section of the device may be increased in an expansion zone 14, so that the velocity of the flow of process gas steadily decreases towards the top. The gas leaves the device as exhaust gas 11 above the expansion zone 14 through an exhaust 19, which may optionally incorporate a dust removal system (e.g. filter cartridges or woven fabric filter elements).

[0073] In the process space 8 there are a number of particles that are carried upward by the process gas jets. The solid particles can be introduced into the process space at the start of the process, but the process can also be started by creating solid particles from an atomized spray composition.

[0074] In the upper region of the process space 8 and in the expansion zone 14 located above, the gas velocity decreases so that the upwardly flowing particles leave the gas jet 23 laterally and return to the process space 8, which is bounded in its lower region by an inclined side wall 29. As a result of this lateral inclination, the particles are transported under the action of gravity through the return zone 24 in the direction of the gas inlet gap 1, where they are again carried by the process gas into the process space 8.

[0075] This mechanism creates a very uniform solids circulation 15 consisting of an upward flow and a return towards the process gas inlet. As a result, even with a very small amount of particles in the process space 8, a high particle density is present in the core zone above the deflection section 3. In this area, one or more spray nozzles 7 are located, which spray upwards in the same direction as the process gas jet and serve to introduce the spray composition.

[0076] The high particle loading in the core zone creates very favorable conditions for heat and mass transfer in the spray zone 22. The spray composition loses liquid rapidly by evaporation. When solid particles already present in the process space come into contact with droplets of the spray composition that may have already lost some of their liquid content, larger particles and particle agglomerates are formed.

[0077] The process gas can exhaust a portion of the particles as well as fine materials and dust from the process space 8 as exhaust air 20 containing solids. To remove these particles, a filter system, optionally integrated in the exhaust 19, or a dust removal system connected downstream of the device can be used. In the case of an integrated dust removal system 25, for example, a compressed air pulse 18 can be used to return the retained particles as separated solids 21 to the process space 8.

[0078] In comparison with fluidized bed apparatuses with integrated filter systems, dust return is facilitated by the fact that the upward process gas flow is essentially localized and thus particles to be returned can safely sink outside the gas jet. This mechanism is further promoted by the suction effect in the vicinity of the gas inlet gap 1. Alternatively, particles separated from the exhaust air can be returned to the process space 8. For this purpose, various types of feeders 26 can be arranged in the lower region of the inclined side wall 29. Due to the high speed of the process gas jet in the vicinity of the gas inlet gap 1, fine particles are drawn in and sent to the spray zone 22, where they are wetted by the spray composition and take part in the growth process.

[0079] Optionally, an integrated guide plate 16 stabilizes particle circulation.

[0080] For continuous process control, the device can optionally be equipped with a different entry system 13 for solids. In this way, for example, particles obtained by grinding (too large) granules and / or consisting of too small granules can be fed to the process. These particles then serve as nuclei for granulation or as starter filling to reduce start-up times. Furthermore, additives to be embedded in the granules can be fed to the process in solid form.

[0081] Furthermore, the device can be provided with a discharge element 4 so that the particles can be removed (removed) from the process space 8. This can be done, for example, via an overflow or via a volumetric discharge element (for example a rotary valve) or via a gravity shifter (for example a zigzag shifter or a riser pipe shifter filled with a shifting gas).

[0082] In order to create by grinding sufficient fine material as nuclei for the granule formation process, optionally a mechanical unit 27 can be attached to the inclined wall of the process space 8, preferably in the region of the return zone 24. Furthermore, optionally, the return zone 24 can be used to place a heater or other heat transfer device 28. For example, the walls of the device can be double-walled, in order to use a liquid or gaseous heat transfer medium to heat or cool the walls. In this way, an optimal surface temperature can be set.

[0083] In the process space 8 or in the parts of the device above it, the expansion zone 14 and the exhaust 19, spray nozzles 6 can be arranged optionally, which preferably spray downwards, but also partly upwards. Here too, a liquid formulation can be injected in order to create granulation nuclei in the device, for example by spray drying / spray solidification. Alternatively, additives and other ingredients can be sprayed in liquid form through parts of the spray devices 6 and 7 and thereby embedded homogeneously in the granule structure. If the spray nozzles 7 pass through the temperature-loaded supply air chamber 17, the liquid-carrying parts can be optionally provided with insulation or various cooling or heating systems 12 to prevent damage to the liquid formulation.

[0084] The advantage of the process according to the invention is a very simple construction, which combines high operational reliability and insensitivity to faults with very good cleaning options, which improves production conditions, especially with regard to medical and hygienic requirements during product changes.

[0085] Another advantage is that the active ingredient used does not have to be milled prior to further processing: after addition of tableting excipients further processing into tablets is possible.

[0086] The process according to the invention makes it possible to produce granules with a high yield, with virtually no loss of active ingredient, since the finely divided material can be returned to the process or, in the case of internal classification, is not discharged at all.

[0087] The present invention also relates to granules produced according to the invention, which are obtainable by the process of the invention and have a diameter of 50 to 1200 μm, for example 100 to 600 μm, preferably 150 to 500 μm. 50 has.

[0088] Additionally or alternatively, the granules have a bulk density of 0.400 to 0.900 g / ml, preferably 0.500 to 0.600 g / ml.

[0089] The product according to the invention is flowable.

[0090] The product according to the invention has a high stability, in particular there is no aggregation or clumping during storage.

[0091] The granules obtained as described above can be further processed into controlled release dosage forms, including in particular dosage forms that release the active ingredient only in the deep intestine, such as the ileum or colon. According to one embodiment, the granule particles are provided with one or more functional coatings to control the release of the active ingredient.

[0092] Appropriately selected coatings dissolve only in the distal part of the small intestine (ileum) and thereafter in the colon, and they control the release of the active ingredient so that at least 60%, preferably at least 70%, in particular at least 80% of the active ingredient is released in the ileum and colon.

[0093] Such a coating can be applied, for example, with the aid of the Wurster process.

[0094] Suitable coating materials are polymeric compositions, in particular those which result in an enteric coating which dissolves at pH values ​​above 6.5, above 6.8, in particular above 7.0.

[0095] Polymers obtained by polymerizing acrylic acid, methacrylic acid and their esters are suitable.

[0096] Preferred polymers are methacrylic acid-methyl methacrylate copolymer (1:2), commercially available as Eudragit® S100 (powder) and Eudragit® S12.5 (organic solution), and methyl acrylate-methyl methacrylate-methacrylic acid copolymer (7:3:1), commercially available as Eudragit® FS30D (aqueous dispersion).

[0097] These polymers can be used alone or in combination with other polymers, such as other Eudragit® types, to tailor the desired release profile.

[0098] Conventional excipients and additives may be mixed with the polymer.

[0099] Instead of coating the granule particles, the granule particles obtained by the process according to the invention can also be processed into tablets or filled into capsules and then coated with one or more coatings to provide a controlled release dosage form. The above information also applies to these coatings.

[0100] The release from the coated tablets or capsules occurs in such a manner that at least 60%, preferably at least 70%, in particular at least 80% of the active ingredient is released in the ileum and colon.

[0101] Evaluation method Particle analysis is performed with the optical image evaluation system Camsizer XT (Retsch). The Camsizer XT uses the principles of digital image processing. The dispersed particle stream passes through two LED strobe light sources. The shadows cast by the particles are recorded by two digital cameras. The particle size is determined as the shortest chord length of a measured set of maximum chord lengths of the particle projections.

[0102] The particle population is characterized by a cumulative value Q3(x) that indicates the volume fraction (%) of particles smaller than x relative to the total volume of particles. The value d 50 indicates the value x at which Q3(x) is 50%.

[0103] The moisture content of the product is measured using a Sartorius MA100 moisture meter (halogen lamp, 105° C., automatic switch-off). The moisture content of the granules according to the invention is typically less than 1% by weight.

[0104] For optical evaluation of the samples, recordings are made with an AXIO microscope (Zeiss).

[0105] To evaluate the material properties, the test samples are measured using a D2 Phaser (Brucker) X-ray diffractometer.

[0106] Bulk volume / bulk density is measured in a graduated cylinder. Carefully pour the sample into the graduated cylinder without compressing the sample (do not knock or bump it).

[0107] After determining the bulk volume / bulk density in the graduated cylinder, the same sample is mechanically tapped in the cylinder (tamping volumeter ERWEKA SVM20) and the volume is read again, until no substantial change in volume is observed.

[0108] Bulk and tamped density are calculated from the mass and bulk density or tamped volume measurements.

[0109] The angle of repose is the angle of inclination of the flow when the product flowing freely from the funnel forms a cone on the surface. Its measurement is carried out using the RTG01 trickle tester. EXAMPLES

[0110] The present invention will now be described with reference to specific application examples, but is in no way limited thereto.

[0111] Example 1 - Preparation of a Spray Composition The metformin hydrochloride to be processed was collected completely in large chunks, which had to be first broken into small pieces, which were then further ground with the help of a rotor-stator mill.

[0112] This was made into a suspension with distilled water to a dry matter content of 50%. The suspension was stirred with a paddle stirrer and then passed through a 500 μm sieve to prevent nozzle clogging. It was found that coarse components were still present in the suspension. The suspension was stirred again with an Ultra Turrax T-50 (IKA) at 10,000 rpm for 10 min. All suspensions for the following experiments were prepared in the same way.

[0113] In further experiments, a solution of metformin hydrochloride was prepared. It was possible to obtain an aqueous solution with a dry matter content of 28%. For this it was necessary to use Ultra Turrax.

[0114] Example 2 - Preparation of Metformin Hydrochloride Product Without Added Excipients Granulation tests were carried out continuously in a laboratory system equipped with a spouted bed insert.

[0115] The spray composition was sprayed with a bottom spray nozzle (two-substance nozzle; nozzle air temperature not heated).

[0116] An aqueous solution of metformin hydrochloride with a dry matter content of 28% was sprayed into the device.

[0117] The spray composition was delivered from a storage container (5 liter container; unheated) to the nozzle using a peristaltic pump.

[0118] Filters were placed above the spouted bed and they were periodically cleaned by blasting with compressed air so that dust remained in the process space.

[0119] The process air was delivered through a speed-controlled exhaust fan. An electric heater was used to heat the air.

[0120] The product discharge was regulated by the air flow in a zigzag sifter and under stable operating conditions the same amount of dry material was discharged as dust-free granules as was delivered in the spray composition.

[0121] The fine dust from the classifier was returned to the process chamber.

[0122] According to the method described, active ingredient pellets consisting of 100% active ingredient were obtained from the solution.

[0123] The process was very stable.

[0124] First, small particles were prepared (sample A; d 50 =123.2μm).

[0125] Next, the spray pressure was reduced and the spray rate was increased to promote particle growth. Then, larger particles could be produced (sample B; d 50 =300.9μm).

[0126] Example 3 - PVP and Particle Size In this example, a suspension of metformin hydrochloride in water was prepared with 5% by weight of PVP Kollidon K-30 (based on dry matter). The dry matter content of this suspension was 51.3%. The process was started with the residual layer from the previous experiment.

[0127] A 2.0 mm nozzle was used. The suspension was sprayed while being stirred.

[0128] d of the product discharged from the process area 50 was 197.6 μm.

[0129] After that, the spray pressure was reduced and the spray rate was increased to promote particle growth. 50 was 423.6 μm.

[0130] The particle size distribution of this product is shown in Figure 2, and a micrograph of a sample is shown in Figure 3. The resulting product particles are seen to be tightly bound spherical agglomerates.

[0131] It was possible to produce different particle sizes in the final product with a PVP content of 5%.

[0132] Example 4 - Throughput In this study, the process needed to be further optimized. For this purpose, an attempt was made to further concentrate the suspension of metformin hydrochloride and PVP in water. A suspension with a dry matter content of 69.4% was obtained. Based on this dry matter content, this suspension also contained 5% PVP.

[0133] Despite the high viscosity, it was possible to spray this suspension and, due to the small amount of water that had to be evaporated, a significant increase in throughput could be achieved (1.3 kg / h in Example 3, 2.9 kg / h in this example).

[0134] First, small grain sizes were also produced here (d 50 = 186.8 μm). Later, larger particles were produced (d 50 = 475.3 μm). The process was completed without any nozzle clogging or other issues.

[0135] Example 5 - Varying Binder Content In this test, the PVP content was reduced from 5% to 2.5% (based on dry matter). The suspension concentration was maintained (68.8%). After replacing the bed mass, the small particles (d 50 = 184.7 μm), followed by coarse particles (d 50 = 269.2 μm) was produced.

[0136] For further testing, a suspension was prepared again (dry matter content 70.2%). This time, only 1% PVP (based on dry matter) was added. Again, the small particle size (d 50 = 165.3 μm). Then, larger particles (d 50 = 230.5 μm) was fabricated.

[0137] In this way particles of various sizes can be produced.

[0138] Example 6 - Flowability Various parameters were determined to draw a conclusion about the flowability of the product.

[0139] The pure active ingredient was slightly deagglomerated for the measurements so that the evaluation could be carried out.

[0140] The Hausner ratio was determined as the ratio of tap density to bulk density. For values ​​close to 1, good dosing accuracy can be expected, whereas for values ​​significantly above 1, the dosing accuracy may be vibration dependent. This example shows that the Hausner ratio of the sample according to the invention is reduced compared to the raw material, thereby improving the dosing accuracy.

[0141] The Carr index was calculated as follows: 100 x (bulk volume - tapped volume) / bulk volume. A lower Carr index indicates better flow behavior. A value below 15 indicates a product with good flowability.

[0142] The smaller the angle of repose, the better the flow behavior.

[0143] [Table 1]

[0144] Example 7 - Stability The samples according to the invention were stored in sealed plastic bags at room temperature for 3 months and maintained good flowability.

[0145] Example 8 - Preparation of tablets Tablets were prepared using the metformin hydrochloride products obtained in some of the previous examples.

[0146] The composition and characteristics of the metformin hydrochloride product used are shown in Table 2 below. [Table 2]

[0147] To prepare the tableting mixture, 1,000 parts by weight of the metformin hydrochloride product were each mixed with 3 parts by weight of magnesium stearate as a release agent and 31 parts by weight of croscarmellose sodium (AcDiSol®) as a disintegrant.

[0148] To produce biconvex tablets, a Fette tablet press (102i) with punch hole diameter of approximately 10 mm was used. The filling depth was 9 mm. A speed of 10,000 tablets per hour was used.

[0149] Further parameters are given in Table 3 below. [Table 3]

[0150] In all cases tablets with acceptable disintegration times could be obtained.

[0151] Example 9 - Preparation of coated granule particles The coated granules are made from metformin hydrochloride granules. The purpose of the coating is to ensure that the active ingredient is released primarily in the ileum and colon.

[0152] Exemplary Coating Suspension Formulations - EUDRAGIT® FS 30 D (available from Evonik Roehm GmbH, Darmstadt, DE) 2000 g - 300 g talc (available from Merck KGaA, Darmstadt, DE) - Triethyl citrate (TEC) (available from Vertellus Inc., Greensboro, USA) 37.5 g -Water (desalinated) 2350g

[0153] To make the coating suspension, EUDRAGIT® FS 30D, talc, and TEC are mixed using a paddle stirrer (IKA GmbH & Co. KG, Staufen, DE). The suspension is passed through a 0.1 mm sieve.

[0154] The suspension has a solids content of 20.0% and a polymer content of 12.8%.

[0155] This suspension is then processed into metformin hydrochloride granules (d 50 = 350 μm). For this purpose, a Glatt GPCG1 fluidized bed system (Glatt GmbH, Binzen, DE) equipped with a 1.2 mm nozzle (top spray) and an atomizing air pressure of 2 bar is used. Further process parameters are a spray rate of 7-10 g / min / kg, an inlet air temperature of 38-40 °C and an outlet temperature of 26-30 °C.

[0156] The suspension is sprayed until 30.0% by weight of polymer is applied, based on the metformin hydrochloride granules used.

[0157] The final product is then dried in the unit. 0.5% Aerosil® 200 (calcined silicon dioxide) is added before drying to prevent clumping. Finally, preferred embodiments of the present invention are described in sections. [Embodiment 1] 1. A method for the continuous production of active ingredient granules, comprising the following steps: (a) preparing a spray composition by dissolving or dispersing the active ingredient and, optionally, one or more excipients in a liquid; (b) providing solid particles to the process space; (c) introducing droplets of the spray composition into an injection zone of the process space where the liquid evaporates; (d) by directing, with the aid of process gas jets, the solid particles repeatedly through the atomized droplets in the process space, at least a part of the droplets, which may have already lost part of their contained liquid, comes into contact with the solid particles and larger solid particles are formed by agglomeration; (e) Removing the active ingredient granules from the process space in the form of solid particles; Including, The method, wherein the active ingredient comprises metformin or an acid addition salt of metformin, particularly metformin hydrochloride. [Embodiment 2] 2. The method of embodiment 1, wherein the active ingredient is metformin hydrochloride. [Embodiment 3] 3. The method of claim 1 or 2, wherein the liquid is water. [Embodiment 4] The method of any one of the preceding claims, wherein the spray composition further comprises a binder. [Embodiment 5] 5. The method according to any one of the preceding claims, wherein the dry matter content of the spray composition is at least 25% by weight. [Embodiment 6] 6. The method according to embodiment 5, wherein the proportion of the active ingredient in the dry matter content is at least 70% by weight. [Embodiment 7] 7. The method of any one of the preceding claims, wherein the spray composition is a suspension. [Embodiment 8] The method according to any one of the preceding embodiments, wherein the providing of particles according to step (b) is carried out by spraying the spray composition into an empty process space and evaporating liquid in the process space. [Embodiment 9] 9. The method according to any one of the preceding embodiments, wherein in step (e) particles that have reached a predetermined size are removed. [Embodiment 10] 9. The method according to any one of the preceding embodiments, wherein solid particles that have not reached a predetermined size are returned to the process space. [Embodiment 11] 11. The method according to any of the preceding embodiments, wherein the excessively large particles are returned to the process space after grinding. [Embodiment 12] d of the particle to be extracted 50 12. The method according to any one of the preceding embodiments, wherein the particle size, expressed as a value, is from 100 to 600 μm. [Embodiment 13] An active ingredient granule produced according to the method according to any one of embodiments 1 to 12, comprising: 50 Active ingredient granules, the particle size of which, expressed as a value, is between 100 and 600 μm. [Embodiment 14] 13. An active ingredient granule produced according to the method of any one of embodiments 1 to 12, which is coated for controlled release. [Embodiment 15] 15. An active ingredient granule according to embodiment 14, wherein the coating controls the release such that at least 60%, preferably at least 70%, or in particular at least 80% of the active ingredient is released in the ileum and colon. [Embodiment 16] 13. Use of an active ingredient granule produced according to the method according to any one of embodiments 1 to 12 for the manufacture of a tablet or capsule. [Embodiment 17] The use of embodiment 16, wherein the tablet or capsule is coated with a controlled release coating. [Embodiment 18] Use according to embodiment 17, wherein the tablet or capsule releases at least 60%, preferably at least 70%, in particular at least 80% of the active ingredient in the ileum and colon. [Explanation of symbols]

[0158] 1 Gap(s) 2 Gas jet(s) 3 Deflection section 4 Emission factors 5 side wall 6 Spray nozzle(s) that spray in any direction 7. Upward spray nozzle(s) 8 Process Space 9 Process Steps 10 Process gas 11 Exhaust gas 12 Insulation and cooling or heating systems 13 Supply System 14 Extended Zone 15 Solid circulation 16 baffle(s) 17 Supply Air Chamber 18 Compressed Air Pulse 19 Exhaust section 20 Exhaust containing solids 21 Separated and Reclaimed Solids 22 Spray Zone 23 Escape of particles from a gas jet 24 Return Zone 25 Dust Removal System 26 Feeder 27 Mechanical assembly for crushing 28 Electric heating device 29 Side wall

Claims

1. 1. A method for the continuous production of active ingredient granules, comprising: (a) preparing a spray composition by dissolving or dispersing an active ingredient and optionally one or more excipients in a liquid; (b) providing solid particles to a process space; (c) introducing droplets of said spray composition into an injection zone of a process space where liquid is evaporated; (d) directing, with the aid of process gas jets, the solid particles so as to repeatedly pass through the atomized liquid droplets in the process space, so that at least a portion of the droplets, which may have already lost a portion of their liquid content, come into contact with the solid particles and larger solid particles are formed by agglomeration; (e) removing the active ingredient granules from the process space in the form of solid particles; Including, The method, wherein the active ingredient comprises metformin or an acid addition salt of metformin.

2. 2. The method of claim 1, wherein the active ingredient is metformin hydrochloride.

3. The method of claim 1 or 2, wherein the liquid is water.

4. The method of any one of claims 1 to 3, wherein the spray composition further comprises a binder.

5. The method according to any one of claims 1 to 4, wherein the dry matter content of the spray composition is at least 25% by weight.

6. 6. The method according to claim 5, wherein the proportion of said active ingredient in the dry matter content is at least 70% by weight.

7. The method according to any one of claims 1 to 6, wherein the spray composition is a suspension.

8. The method according to any one of claims 1 to 7, wherein the providing of particles according to step (b) is carried out by spraying a spray composition into an empty process space and evaporating a liquid within the process space.

9. The method according to any one of claims 1 to 8, wherein in step (e) particles that reach a predetermined size are removed.

10. The method according to any one of the preceding claims, wherein solid particles which have not reached a predetermined size are returned to the process space.

11. The method according to any one of the preceding claims, wherein the excessively large particles are returned to the process space after comminution.

12. d of the particle to be taken out ５０ The method according to any one of claims 1 to 11, wherein the particle size, expressed as a value, is between 100 and 600 μm.

13. An active ingredient granule produced according to the method of any one of claims 1 to 12, comprising: ５０ Active ingredient granules having a particle size expressed as a value between 100 and 600 μm.

14. 13. An active ingredient granule produced according to the method of any one of claims 1 to 12, which is provided with a coating for controlled release.

15. 15. The active ingredient granule according to claim 14, wherein the coating controls the release such that at least 60% of the active ingredient is released in the ileum and colon.

16. Use of an active ingredient granule produced according to the method according to any one of claims 1 to 12 for the manufacture of a tablet or capsule.

17. 17. The use according to claim 16, wherein the tablet or capsule is coated with a controlled release coating.

18. 18. The use according to claim 17, wherein the tablet or capsule releases at least 60% of the active ingredient in the ileum and colon.

Images